References
- Adam D. Challenges in the management of serious infections in pediatric patients. Pediatr Infect Dis J 1996; 15: 729–32.
- Heusser MF, Patterson JE, Kuritza AP, Edberg SC, Baltimore RS. Emergence of resistance to multiple I3-lactams in Enterobacter cloacae during treatment for neonatal menin-gitis with cefotaxime. Pediatr Infect Dis J 1990; 9: 509–12.
- Sirot DL, Goldstein FW, Soussy CJ, et al. Resistance to cefotaxime and seven other I3-lactams in members of the fam-ily Enterobacteriaceae: a 3-year survey in France. Antimicrob Agents Chemother 1992; 36: 1677-81.
- Thomson KS, Sanders CC, Washington JA. High-level resistance to cefotaxime and ceftazidime in Klebsiella pneu-moniae isolates from Cleveland, Ohio. Antimicrob Agents Chemother 1991; 35: 1001–3.
- Figueiredo AMS, Connor JD, Severin A, Pato MVV, Tomasz A. A pneumococcal isolate with high-level resistance to cefotaxime and ceftriaxone. Antimicrob Agents Chemother 1992; 36: 886–9.
- Frienland IR, Klugman KP. Advance in the management of penicillin-resistant pneumococcal meningitis. South Afr Med J 1992; 81: 341–2.
- Rains CP, Bryson HM, Peters DH. Ceftazidime: an update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1995; 49: 577–617.
- Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995; 36 (suppl. A): 1-17.
- Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36 (suppl. A): 207-223.
- Fujii R, Yoshioka H, Fujiita K, et al. Pharmacokinetic and clinical studies with meropenem in the pediatric field. J Antibiot 1992; 45: 697–717.
- Bradley JS, Faulkner KL, Klugman KP. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatr Infect Dis J 1996; 15: 749–57.
- Hoiby N, Johansen H K, Koch C, Jensen T, Pressler T. Use of carbapenems and other antibiotics for pulmonary infec-tions in patients with cystic fibrosis. Pediatr Infect Dis J 1996; 15: 738–43.
- Cometta A, Viscoli C, Castagnola E, et al. Empirical treatment of fever in neutropenic children: the role of the car-bapenems. Pediatr Infect Dis J 1996; 15: 744–8.
- Nalin DR, Jacobsen CA. Imipenem/cilastatin therapy for serious infections in neonates and infants. Scand J Infect Dis 1987; (Suppl) 52: 46-55.
- Wong VK, Wright HT, Ross LA, Mason WH, Inderlied CB, Kim KS. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991; 10: 122–5.